公开(公告)号：US20110176998A1

公开(公告)日：2011-07-21

申请号：US12903842

申请日：2010-10-13

申请人： Martin G. Pomper ,  Richard Ambinder ,  Jun O. Liu ,  Curtis R. Chong ,  Jianmeng Chen

发明人： Martin G. Pomper ,  Richard Ambinder ,  Jun O. Liu ,  Curtis R. Chong ,  Jianmeng Chen

IPC分类号： A61K51/00 ,  C07F5/02 ,  C07C229/66 ,  C07D261/18 ,  C07D235/32 ,  C07H19/09 ,  C07D209/46 ,  C07F5/00 ,  C07F9/00 ,  C12Q1/70 ,  C12N5/09 ,  A61P29/00 ,  A61P31/12 ,  A61P35/00 ,  A61P31/04

CPC分类号： A61K51/0491 ,  A61K31/00 ,  A61K31/192 ,  A61K31/403 ,  A61K31/4168 ,  A61K31/42 ,  A61K31/7068 ,  A61K33/22 ,  A61K45/06 ,  A61K2300/00 ,  Y02A50/402 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/479

摘要： The present invention features compositions and methods for detecting, selecting a treatment method for, monitoring, and treating a neoplasia associated with a viral infection.

摘要翻译： 本发明的特征在于用于检测，选择与病毒感染相关的瘤形成的治疗方法，监测和治疗的组合物和方法。

公开(公告)号：US20060233770A1

公开(公告)日：2006-10-19

申请号：US10528311

申请日：2003-09-19

申请人： Richard Ambinder ,  Yiping Yang ,  Ivan Borrello ,  Hyam Levitsky

发明人： Richard Ambinder ,  Yiping Yang ,  Ivan Borrello ,  Hyam Levitsky

IPC分类号： A61K48/00 ,  C12N5/08

CPC分类号： A61K39/0011 ,  A61K2039/5156 ,  A61K2039/54 ,  A61K2039/55522 ,  C07K14/005 ,  C12N2710/16222

摘要： A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or stimulating an immune response in a human to a viral-associated disease or cancer comprising administering to the human (i) the aforementioned human cell line in an amount sufficient to induce or stimulate an immune response to the viral associated disease or cancer, (ii) a human cell line, which lacks MHC-I and MHC-11 antigens and which has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficient to induce or stimulate an immune response to the viral-associated disease or cancer, or (iii) an immunomodulator and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficient to induce or stimulate an immune response to the viral associated disease or cancer.